$0.68
-0.02 (-2.43%)
Open$0.73
Previous Close$0.70
Day High$0.73
Day Low$0.68
52W High$2.34
52W Low$0.55
Volume—
Avg Volume69.7K
Market Cap8.02M
P/E Ratio—
EPS$-2.14
SectorBiotechnology
Analyst Ratings
Strong Buy
9 analysts
Price Target
+5,179.6% upside
Current
$0.68
$0.68
Target
$36.06
$36.06
$23.45
$36.06 avg
$38.88
Key Financials
| FY 2026 | FY 2025 | FY 2024 | |
|---|---|---|---|
| Revenue | 2.87M | 1.10M | 1.13M |
| Net Income | -24,736,964 | 89.2K | 117.7K |
| Profit Margin | -862.4% | 8.1% | 10.4% |
| EBITDA | -27,291,753 | 177.4K | 182.1K |
| Free Cash Flow | — | 70.9K | 72.7K |
| Rev Growth | — | +5.3% | -7.0% |
| Debt/Equity | — | 0.17 | 0.19 |
Biotechnology Peers
| Symbol | Name | Price | Change | P/E | Mkt Cap |
|---|---|---|---|---|---|
| ABBV | Abbvie Inc | $217.49 | +2.05% | 166.6 | 397.77B |
| AMGN | Amgen Inc | $351.85 | +0.82% | 24.7 | 190.40B |
| GILD | Gilead Sciences Inc | $139.37 | +2.22% | 19.6 | 166.66B |
| VRTX | Vertex Pharmaceuticals Inc | $446.54 | +0.76% | 29.1 | 114.87B |
| REGN | Regeneron Pharmaceuticals | $772.64 | +3.12% | 17.9 | 80.50B |
| ALNY | Alnylam Pharmaceuticals Inc | $330.87 | +4.68% | 139.7 | 43.84B |